In conclusion, we have confirmed an anti-cancer effect of both immunotherapies anti-CTLA-4 and anti-PD-1 in syngeneic tumor models with colorectal and triple negative breast cancer cells. This evidence concerns the gene CTLA4 and triple-negative breast carcinoma.